Skip to main content

Table 3 Motivations identified by firm representatives

From: Corporate social responsibility in global health: an exploratory study of multinational pharmaceutical firms

 

A

B

C

D

E

F

Reputational benefit

      

Perception of firm by consumers

X

X

X

X

  

Perception of firm by potential funders

   

X

  

Relationship and trust building with potential partners and stakeholders

X

X

   

X

Employee recruitment, satisfaction, engagement and innovation

X

X

 

X

X

 

Ranking on Dow Jones Sustainability Index*

   

X

X

X

Competetive advantage

      

Entering new markets

X

 

X

X

X

X

Expanding consumer base

     

X

Intelligence gathering on new markets

 

X

    

Anticipated long-term financial gain

X

 

X

X

 

X

Increased cost-effectiveness of interventions and programs (in developing countries)

  

X

   

Improved efficiencies

    

X

 

Opportunity for innovation

X

    

X

Special access to local government officials and decision making

   

X

  

Philanthropy & health impact

      

Obligation as a health care company

   

X

 

X

Improved population health impact

X

X

X

X

X

X

Increasing patient access to necessary medications/health services

X

X

X

X

X

X

  1. *and/or Access to Medicine Index, Fortune World’s Most Admired Companies.